Inhibrx (INBX) Director Kimberly Manhard Sells 1,000 Shares

What Happened Kimberly Manhard, a director of Inhibrx Biosciences, sold a total of 1,000 shares in two open-market transactions. She sold 500 shares on 2026-09-08 at $115.14 each (proceeds $57,570) and 500 shares on 2026-09-09 at $115.80 each (proceeds $57,898), for combined gross proceeds of $115,468. These were sales (dispositions), which are often routine liquidity events rather than direct indicators of company outlook.

Key Details

• Transaction dates and prices: 2026-09-08 — 500 shares @ $115.14; 2026-09-09 — 500 shares @ $115.80.
• Total shares sold: 1,000; total proceeds: $115,468.
• Filing: Form 4 filed 2026-09-10 (appears timely under the 2-business-day rule).
• Shares owned after transaction: Not specified in this filing.
• Footnote: The shares are directly owned by the Kimberly Joan Manhard Revocable Trust (dated 6/4/2012). Ms. Manhard is a trustee and may be deemed to indirectly beneficially own the trust’s securities (Footnote F1).
• Transaction code: S (sale); no 10b5-1 plan, option exercise, gift, or tax-withholding noted.

Context Open-market sales by directors are common for personal liquidity (e.g., diversification, taxes, or personal needs) and do not necessarily reflect a change in company prospects. Retail investors should consider these sales alongside other insider activity, company fundamentals, and broader market factors before drawing conclusions.